It’s also about taking steps to ensure patient engagement, retention and treatment adherence over the course of a study. To determine how precision medicine supports these objectives, Informa Pharma Intelligence conducted an online survey for NTT DATA between Nov. 20 and Dec. 3, 2019. Here’s what that research revealed.
81% of respondents say understanding patient populations is the most important step in developing a precision medicine program
67% of respondents believe that oncology is the seedbed for precision medicine
49% perceive patient awareness, access and enrollment as the biggest obstacles to precision medicine in clinical trials
HCLS Insights Powered by Nucleus, our advanced analytics platform, provides the necessary tools for trial site identification, investigator and physician targeting, biomarker progression, and more. This provides a foundation for improved patient outcomes, greater degrees of quality, and cost efficiencies required for success.
What’s the role of precision medicine in the future of clinical trials?
Our research may surprise you. See what respondents had to say.